Method and composition for therapeutic management of gluten intolerance

Patent metadata

Field	Value
Publication number	US-11419906-B2
Application number	US-202016836066-A
Country	US
Kind code	B2
Filing date	Mar 31, 2020
Priority date	Apr 2, 2019
Publication date	Aug 23, 2022
Grant date	Aug 23, 2022

Abstract

The present invention discloses the potential of probiotic bacteria Bacillus coagulans individually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprising Bacillus coagulans and multi-enzyme complex in mammals.

First claim

We claim:

1. A method for the therapeutic management of gluten intolerance and related conditions in mammals by enhancing gluten utilization, said method. comprising step of administering a composition comprising an effective dose of probiotic bacteria Bacillus coagulans MTCC 5856 individually or in combination with multi-enzyme complex to mammals in need of such therapy to bring about a reduction is symptoms of gluten intolerance.

2. The method as in claim 1 , wherein the effective dose of Bacillus coagulans MTCC 5856 is 2×10 9 colony forming units (cfu).

3. The method as in claim 1 , wherein the probiotic bacteria Bacillus coagulans MTCC 5856 is in combination with the multi-enzyme complex comprises of a) α-amylase: not less than 24000 U/g, b) cellulase: not less than 1100 CU/g, c) lipase: not less than 200 FIP/g, d) lactase: not less than 4000 ALU/g and e) neutral or acid protease: not less than 6000 PC/g.

4. The method as in claim 1 , wherein the related conditions of gluten intolerance are selected from the group consisting of celiac disease, dermatitis herpetiformis, gluten ataxia, non-celiac gluten sensitivity (NCGS), gluten ingestion, Gluten malabsorption.

5. The method as in claim 1 , wherein the mammal is human.

6. The method as in claim 1 , wherein the composition comprising Bacillus coagulans MTCC 5856 individually or in combination with multi-enzyme complex is formulated with pharmaceutically/nutraceutically acceptable excipients, adjuvants, bases, diluents, carriers, conditioning agents, bioavailability enhancers, antioxidants and preservatives and is an orally administered composition in form of tablets, capsules, syrups, gummies, powders, suspensions, emulsions, chewables, candies or eatables.

Assignees

• Majeed Muhammed
• Nagabhushanam Kalyanam
• Beede Kirankumar
• Arumugam Sivakumar
• Majeed Shaheen
• Sami Sabinsa Group Ltd

Inventors

• Majeed Muhammed
• Nagabhushanam Kalyanam
• Beede Kirankumar
• Arumugam Sivakumar
• Majeed Shaheen

Classifications

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61K38/47

  acting on glycosyl compounds (3.2), e.g. cellulases, lactases · CPC title

• C12Y302/01108

  Lactase (3.2.1.108) · CPC title

• A61K38/54

  Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53 · CPC title

• C12Y301/01003

  Triacylglycerol lipase (3.1.1.3) · CPC title